Literature DB >> 20132841

The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A.

Helen Waller1, Udayan Chatterji, Philippe Gallay, Tanya Parkinson, Paul Targett-Adams.   

Abstract

Cyclosporine A (CsA) is an immunosuppressive molecule that also impedes replication of hepatitis C virus (HCV). CsA inhibits isomerase activity of cellular-encoded cyclophilin proteins, of which cyclophilin A (CypA) in particular is required for HCV replication. Evidence suggests that the HCV-encoded NS5A and NS5B proteins may govern dependence of the virus on CypA-mediated isomerase activity, although the molecular mechanisms involved are unclear. However, association of NS5A and NS5B, with CypA has been reported, raising the possibility that direct interaction between these proteins facilitates HCV replication. In the present study, mammalian two-hybrid and AlphaLISA technologies were utilized to detect interactions between NS5A and NS5B, with CypA. AlphaLISA analysis revealed associations between NS5A and CypA using purified proteins, and in cell lysates prepared from co-transfected cells. Importantly, the NS5A-CypA interactions were sensitive to CsA in a dose-responsive manner and an isomerase mutant of CypA interacted with NS5A less efficiently than wild-type CypA. These findings correlate the anti-HCV properties of CsA with an ability of the compound to disrupt NS5A-CypA interactions in vitro and in vivo, whilst providing the basis for development of assay platforms suitable to screen compound libraries for novel inhibitors of the NS5A-CypA interaction. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20132841      PMCID: PMC6634308          DOI: 10.1016/j.jviromet.2010.01.020

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  59 in total

Review 1.  Replication of hepatitis C virus.

Authors:  Darius Moradpour; François Penin; Charles M Rice
Journal:  Nat Rev Microbiol       Date:  2007-05-08       Impact factor: 60.633

2.  Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase.

Authors:  Koichi Watashi; Naoto Ishii; Makoto Hijikata; Daisuke Inoue; Takayuki Murata; Yusuke Miyanari; Kunitada Shimotohno
Journal:  Mol Cell       Date:  2005-07-01       Impact factor: 17.970

3.  Specific incorporation of cyclophilin A into HIV-1 virions.

Authors:  E K Franke; H E Yuan; J Luban
Journal:  Nature       Date:  1994-11-24       Impact factor: 49.962

4.  Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro.

Authors:  Feng Yang; Jason M Robotham; Heather B Nelson; Andre Irsigler; Rachael Kenworthy; Hengli Tang
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

5.  A novel class of small molecule inhibitors of Hsp90.

Authors:  Fang Yi; Lynne Regan
Journal:  ACS Chem Biol       Date:  2008-09-12       Impact factor: 5.100

6.  Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition.

Authors:  L D Zydowsky; F A Etzkorn; H Y Chang; S B Ferguson; L A Stolz; S I Ho; C T Walsh
Journal:  Protein Sci       Date:  1992-09       Impact factor: 6.725

7.  Screening for antiviral inhibitors of the HIV integrase-LEDGF/p75 interaction using the AlphaScreen luminescent proximity assay.

Authors:  Yan Hou; Debra E McGuinness; Andrew J Prongay; Boris Feld; Paul Ingravallo; Robert A Ogert; Charles A Lunn; John A Howe
Journal:  J Biomol Screen       Date:  2008-05-14

8.  The isomerase active site of cyclophilin A is critical for hepatitis C virus replication.

Authors:  Udayan Chatterji; Michael Bobardt; Suganya Selvarajah; Feng Yang; Hengli Tang; Noayo Sakamoto; Gregoire Vuagniaux; Tanya Parkinson; Philippe Gallay
Journal:  J Biol Chem       Date:  2009-04-20       Impact factor: 5.157

9.  Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance.

Authors:  Joanna E Mathy; Sue Ma; Teresa Compton; Kai Lin
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

10.  Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles.

Authors:  Mair Hughes; Stephen Griffin; Mark Harris
Journal:  J Gen Virol       Date:  2009-03-04       Impact factor: 3.891

View more
  21 in total

Review 1.  Chaperones in hepatitis C virus infection.

Authors:  Ronik Khachatoorian; Samuel W French
Journal:  World J Hepatol       Date:  2016-01-08

Review 2.  Host-targeting agents in the treatment of hepatitis C: a beginning and an end?

Authors:  James M Baugh; Jose A Garcia-Rivera; Philippe A Gallay
Journal:  Antiviral Res       Date:  2013-09-30       Impact factor: 5.970

3.  Correlation between NS5A dimerization and hepatitis C virus replication.

Authors:  Precious J Lim; Udayan Chatterji; Daniel Cordek; Suresh D Sharma; Jose A Garcia-Rivera; Craig E Cameron; Kai Lin; Paul Targett-Adams; Philippe A Gallay
Journal:  J Biol Chem       Date:  2012-07-16       Impact factor: 5.157

4.  Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir.

Authors:  Jose A Garcia-Rivera; Michael Bobardt; Udayan Chatterji; Sam Hopkins; Matthew A Gregory; Barrie Wilkinson; Kai Lin; Philippe A Gallay
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

5.  A conserved tandem cyclophilin-binding site in hepatitis C virus nonstructural protein 5A regulates Alisporivir susceptibility.

Authors:  Henry Grisé; Stephen Frausto; Timothy Logan; Hengli Tang
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

6.  HCV NS5A and IRF9 compete for CypA binding.

Authors:  Michael Bobardt; Sam Hopkins; James Baugh; Udayan Chatterji; Felicia Hernandez; John Hiscott; Ann Sluder; Kai Lin; Philippe A Gallay
Journal:  J Hepatol       Date:  2012-08-15       Impact factor: 25.083

7.  The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes.

Authors:  Sam Hopkins; Michael Bobardt; Udayan Chatterji; Jose A Garcia-Rivera; Precious Lim; Philippe A Gallay
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

8.  Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action.

Authors:  Paul Targett-Adams; Emily J S Graham; Jenny Middleton; Amy Palmer; Stephen M Shaw; Helen Lavender; Philip Brain; Thien Duc Tran; Lyn H Jones; Florian Wakenhut; Blanda Stammen; David Pryde; Chris Pickford; Mike Westby
Journal:  J Virol       Date:  2011-04-20       Impact factor: 5.103

Review 9.  Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.

Authors:  Precious J Lim; Philippe A Gallay
Journal:  Curr Opin Virol       Date:  2014-05-27       Impact factor: 7.090

Review 10.  Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection.

Authors:  Sam Hopkins; Philippe Gallay
Journal:  Viruses       Date:  2012-10-29       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.